Roivant Sciences (ROIV) Net Margin (2020 - 2024)
Roivant Sciences (ROIV) reported Net Margin of 3626.3% for Q4 2024, up 400082.0% on a YoY basis from N/an in Q1 2024, and up 476.66% quarter-over-quarter from 962.75% in Q3 2024.
Roivant Sciences (ROIV) Net Margin (2020 - 2024) Analysis & Trends
Roivant Sciences has reported Net Margin for 5 years, with the latest figure at 3626.3% in Q4 2024.
- For the quarter ending Q4 2024, Net Margin rose 400082.0% year-over-year to 3626.3%; the trailing twelve-month figure through Sep 2025 stood at 1897.53% (up 193627.0% YoY), and the FY2025 full-year result was 1284.5%, up 224368.0% from the prior year.
- Net Margin for Q4 2024 stood at 3626.3%, up from 962.75% in the prior quarter.
- The five-year high for Net Margin was 3626.3% in Q4 2024, with the low at 8191.34% in Q2 2022.
- Historically, Net Margin has averaged 1798.14% across 5 years, with a median of 1516.12% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin slumped 688458 bps — and 2023, when it soared 667522 bps.
- Roivant Sciences' Net Margin stood at 4792.99% in 2020, then jumped by 74 bps to 1257.49% in 2021, then plunged by 79 bps to 2257.19% in 2022, then jumped by 83 bps to 374.51% in 2023, then surged by 1068 bps to 3626.3% in 2024.
- The last three Net Margin figures came in at 3626.3% (Q4 2024), 962.75% (Q3 2024), and 1115.06% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,626.30% |
| Sep 30, 2024 | -962.75% |
| Jun 30, 2024 | 1,115.06% |
| Dec 31, 2023 | -374.51% |
| Sep 30, 2023 | -2,370.50% |
| Jun 30, 2023 | -1,516.12% |
| Dec 31, 2022 | -2,257.19% |
| Sep 30, 2022 | -2,520.71% |
| Jun 30, 2022 | -8,191.34% |
| Dec 31, 2021 | -1,257.49% |
| Sep 30, 2021 | -1,613.21% |
| Jun 30, 2021 | -1,306.76% |
| Dec 31, 2020 | -4,792.99% |
| Sep 30, 2020 | -4,043.69% |
| Jun 30, 2020 | -506.15% |